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Abstract
Background: A recent genome-wide association study (GWAS) has identified a single nucleotide polymorphism (SNP) 
rs11249433 in the 1p11.2 region as a novel genetic risk factor for breast cancer, and this association was stronger in 
patients with estrogen receptor (ER)+ versus ER- cancer.
Results: We found association between SNP rs11249433 and expression of the NOTCH2 gene located in the 1p11.2 
region. Examined in 180 breast tumors, the expression of NOTCH2 was found to be lowest in tumors with TP53 
mutations and highest in TP53 wild-type/ER+ tumors (p = 0.0059). In the latter group, the NOTCH2 expression was 
particularly increased in carriers of the risk genotypes (AG/GG) of rs11249433 when compared to the non-risk AA 
genotype (p = 0.0062). Similar association between NOTCH2 expression and rs11249433 was observed in 60 samples of 
purified monocytes from healthy controls (p = 0.015), but not in total blood samples from 302 breast cancer patients 
and 76 normal breast tissue samples. We also identified the first possible dominant-negative form of NOTCH2, a 
truncated version of NOTCH2 consisting of only the extracellular domain.
Conclusion: This is the first study to show that the expression of NOTCH2 differs in subgroups of breast tumors and by 
genotypes of the breast cancer-associated SNP rs11249433. The NOTCH pathway has key functions in stem cell 
differentiation of ER+ luminal cells in the breast. Therefore, increased expression of NOTCH2 in carriers of rs11249433 
may promote development of ER+ luminal tumors. Further studies are needed to investigate possible mechanisms of 
regulation of NOTCH2 expression by rs11249433 and the role of NOTCH2 splicing forms in breast cancer development.
Background
Several genome-wide association studies (GWAS) in
individuals of European ancestry have identified novel
genomic regions associated with risk of breast cancer
(BC) [1-7]. One of the associated variants was a single
nucleotide polymorphism (SNP) rs11249433 located
within the pericentromeric region on chromosome
1p11.2 [4]. The association was found to be stronger with
estrogen receptor (ER)+ than with ER- cancer [4].
Decreased genetic recombination rates within pericen-
tromeric regions can contribute to large linkage disequi-
librium (LD) blocks [8]. As a result, rs11249433 might be
in LD with many other variations located over a large dis-
tance. The region surrounding rs11249433 is poorly cov-
ered in the International HapMap project [9] due to a
high degree of segmental duplications that map to both
sides of centromere on chromosome 1. However,
rs11249433 itself is located in a region uniquely mapped
to 1p11.2. Given the complicated genomic landscape, we
did not perform fine-mapping or resequencing studies of
this region, but sought to identify a possible molecular
phenotype functionally important for breast carcinogen-
esis and related to this genetic association.
The heterogeneity of BC includes diverse molecular
characteristics, and variations in clinical outcomes and
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Page 2 of 11treatment responses. BC patients can be categorized into
different groups based on cellular morphology and
expression of estrogen receptor (ER), progesterone recep-
tor (PR), and human epidermal growth factor receptor 2
(HER-2) [10]. Mutational status of TP53, a tumor sup-
pressor gene, is also of strong prognostic significance for
BC [11]. Previous findings from mRNA expression profil-
ing have identified several molecular categories of BC,
such as luminal-A, luminal-B, normal breast-like, HER-2
positive and basal-like types [12-14]. These categories
represent clinically distinct patient groups [13,14], and
correspond to different breast tumor subtypes with
respect to ER and TP53 mutation status: ER+ tumors are
generally identified as luminal-like subtype [14], while
tumors with TP53 mutations usually belong to the basal-
like type [15].
In this study, we observed a distinct expression profile
of the NOTCH2 gene in various tumor subtypes. Further-
more, the association between rs11249433 and increased
expression of NOTCH2 was found in patients with ER+
breast tumors without TP53 mutations. We also identi-
fied a unique splicing form of NOTCH2 consisting of only
the extracellular domain and thus predicted to have a
dominant-negative function compared to the full-length
form of the gene.
Results and Discussion
NOTCH2 as a candidate gene for BC risk in the 1p11.2 
region
Several studies have shown that cancer-associated SNPs
identified by GWAS are regulatory variants that can be
linked to altered gene expression [16-19]. Working under
the hypothesis that the BC-associated rs11249433 may
regulate mRNA expression of genes in the surrounding
region, we analyzed microarray data for the expression of
five genes located within a 1 Mb region telomeric from
rs11249433 (ADAM30, NOTCH2, NOTCH2NL,
FAM72B, and SRGAP2). There were no genes between
this SNP and the centromere (Figure 1). Two other genes
from this region, LOC647121, a non-coding pseudogene,
and FCGR1B, which belongs to a family of highly similar
genes, were not present on the array and thus were not
examined here. Based on expression analysis in 108
breast tumor samples, there was a suggestive association
between rs11249433 risk genotypes (AG and GG) and
increased expression of the Notch homolog 2 gene
(NOTCH2, p = 0.054) and decreased expression of the
Notch homolog 2 N-terminal-like gene (NOTCH2NL, p =
0.038) (Table 1). The four known NOTCH proteins
(NOTCH1 - 4) are highly conserved transmembrane
receptors found in all multicellular organisms [20]. Inter-
actions between membrane-bound ligands Jagged1,
Jagged2, Delta1 and the extracellular domains of NOTCH
proteins trigger a cascade of proteolytic cleavages that
result in a release of the notch intracellular domain
(NICD) and induced expression of target genes involved
in response to hypoxia, stem cell maturation, migration
and inhibition of differentiation [20-22]. The NOTCH
signaling pathway has been well-studied as one of the
underlying mechanisms and potential therapeutic targets
for BC [23,24]. However, the majority of information
about the NOTCH pathway is related to NOTCH1 gene,
while the potential role of NOTCH2 gene is still not well
established. Interestingly, a recent report indicated that a
higher expression level of NOTCH2 can be found in low-
grade/well-differentiated breast tumors as compared to
poorly-differentiated tumors [25].
Exons 2 - 4 of NOTCH2 are included in NOTCH2NL
gene, and this region is duplicated at 1q21.1, on the other
side of centromere, while exons 5 - 34 of NOTCH2 are
uniquely mapped to the 1p11.2 region. The full-length
NOTCH2 has 34 exons that encode a protein of 2471
amino acids with an extracellular domain containing
multiple epidermal growth factor (EGF)-like repeats, and
NOTCH2NL has 4 exons and encodes a protein of 235
amino acids with only one EGF-like repeat. The role of
NOTCH2NL is not clear and, given its mapping to multi-
ple locations and the lack of protein domains, expression
of NOTCH2NL was not studied further.
NOTCH2 expression analysis
To corroborate our observations of the suggestive associ-
ation between rs11249433 and NOTCH2 expression, we
employed the sensitive and quantitative reverse-tran-
scriptase PCR (RT-PCR) method in an extended set of
180 breast tumors, 104 of which were used for the initial
microarray analysis. We used a custom-designed expres-
sion assay for terminal exons 33 and 34 of NOTCH2 to
detect the full-length transcripts (FL-NOTCH2). Expres-
sion of FL-NOTCH2 was increased in tumors from indi-
viduals with risk genotypes AG and GG of rs11249433
compared to non-risk AA genotypes by 1.24 and 1.12
fold, respectively (p = 0.066, Additional File 1, Table S1).
The expression was found to be significantly increased in
tumors from patients with higher age at diagnosis (p =
0.0007) and decreased in tumors with TP53 mutations (p
= 0.0056, Additional File 1, Table S1). However, no associ-
ation was observed between NOTCH2 expression and
tumor grade or stage (data not shown).
The tumor suppressor gene TP53 regulates multiple
vital cell functions. Germline TP53 mutations found in
patients with Li-Fraumeni syndrome [26] are associated
with early development of tumors, while the restoration
of the gene function causes regression of tumors by apop-
tosis and senescence [27]. Somatic mutations in the TP53
gene are found in 20 - 30% of all breast tumors [28,29],
but the frequency varies by tumor stage and subtype. For
example, more than 80% of basal-like tumors, while only
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Since different subtypes of BC have been associated with
distinct gene expression profiles [12-14], we examined
the NOTCH2 expression in subgroups of breast tumors
according to their ER and TP53 status. There was a
strong difference in NOTCH2 expression in these sub-
groups (p = 0.0059, Figure 2A and Additional File 1, Table
S1), the expression was lower in tumors with TP53 muta-
tions. In tumors with wild-type (wt) TP53 gene,
NOTCH2 expression was higher in ER+ compared to ER-
tumors. Among patients with TP53wt/ER+ tumors,
NOTCH2 expression was increased by 1.52 and 1.11 fold
in individuals with the risk AG and GG genotypes,
respectively, compared to those with the non-risk AA
genotype of rs11249433 (p = 0.0062, Figure 2B and Addi-
tional File 1, Table S1). SNP rs11249433 is located ~600
kb away from NOTCH2. The non-linear increase of
NOTCH2 expression with allele counts may indicate that
rs11249433 is not the actual risk factor but is in LD with
the best candidate that can be located at any distance.
There was no association of rs11249433 with NOTCH2
expression in RNA from peripheral blood of 302 women
with a previous breast cancer diagnosis (Additional File 1,
Table S2), or in 76 samples of adjacent normal breast tis-
sue (Additional File 1, Table S3). According to GNF
Expression Atlas 2 data http://biogps.gnf.org/
#goto=genereport&id=4853 and results by Ohishi et al.
[30], the highest NOTCH2 expression of all blood frac-
tions is found in monocytes while it is low in all other
blood cells. Using purified peripheral blood monocytes
from 60 healthy controls, we observed that individuals
carrying risk genotypes of rs11249433 had significant
increase of NOTCH2 expression (p = 0.015, Additional
File 1, Table S4), similar to the pattern in breast tumors.
The pericentromeric NOTCH2 region is reported to
contain large structural variations (amplifications and
deletions) detectable by high-resolution comparative
genomic hybridization (CGH) analysis [31]. We hypothe-
sized that these copy number variations (CNVs) might
affect mRNA expression of NOTCH2, and measured
CNVs by two quantitative PCR assays located in intron 1
and upstream from NOTCH2. We used DNA from breast
tumors (n = 97) and blood samples from BC patients (n =
295) in which expression analysis was performed.
NOTCH2 expression was not significantly correlated with
CNVs in both samples (Additional File 1, Table S5). Inclu-
sion of CNVs into the multivariable model did not affect
the association between rs11249433 and NOTCH2
expression (Additional File 1, Table S6). Another SNP,
rs10923931, located within intron 2 of NOTCH2 has been
reported to be associated with risk of type 2 diabetes [32].
We did not observe any effect of rs10923931 on NOTCH2
Figure 1 Genomic organization of the 1p11.2 region surrounding the BC-associated rs11249433. The map is based on genome build hg18 
http://genome.ucsc.edu/ and shows genes, dbSNPs(130), HapMap SNPs (rel27) and structural variations.
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S1) or in blood of BC patients (Additional File 1, Table
S2).
Assessment of possible NOTCH2 function through 
expression and pathway analyses in NCI-60 cell lines
NOTCH2 belongs to a family of transmembrane recep-
tors involved in regulation of cell-cell communication,
cell proliferation, differentiation, and apoptosis [33].
However, the specific role of NOTCH2 is not yet well
established. To assess the potential function of NOTCH2,
we used expression data generated in 60 human cell lines
representing several cancer types (NCI-60 cell line
expression set [34]). We examined correlation patterns
between NOTCH2 and all the genes represented on
Affymetrix HG-U133 arrays, as previously described
[35]. After adjustment for multiple comparisons, 469 and
758 genes showed significantly positive and negative cor-
relations with NOTCH2, respectively. These genes were
analyzed for enrichment of Gene Ontology (GO) catego-
ries. The analysis identified statistically significant
enrichment of the integrin signaling pathway (p = 1.87 ×
10-7) and cell structure and motility (p = 6.96 × 10-9) for
genes with positive correlations with NOTCH2, and
enrichment for nucleic acid binding (p = 1.88 × 10-17) and
nucleoside, nucleotide and nucleic acid metabolism (p =
1.20 × 10-10) for genes with negative correlations with
NOTCH2 (Table 2). These results supported the potential
role of NOTCH2 in maintaining cell shape, structure and
motility [36], and NOTCH-mediated regulation of integ-
rin affinity [37].
Table 1: Results of microarray analysis for 5 genes within 1 Mb from rs11249433 in the 1p11.2 region.
Gene/SNP Position, bp+ rs11249433 N Fold* 95%CI p-value*
ADAM30 chr1: 120,237,679 - 
120,240,636
AA 35 1.00 0.90 - 1.11 0.378
AG 41 1.06 0.96 - 1.16
GG 13 0.93 0.80 - 1.09
NOTCH2 chr1: 120,279,260 - 
120,413,799
AA 41 1.00 0.85 - 1.18 0.054
AG 45 1.28 1.10 - 1.50
GG 17 1.16 0.91 - 1.46
NOTCH2NL chr1: 120,338,694 - 120,398-
362
AA 41 1.00 0.75 - 1.33 0.038
chr1: 143,920,468 - 
144,009,723
AG 47 0.64 0.49 - 0.83
GG 19 0.70 0.47 - 1.04
FAM72B chr1: 120,640,935 - 
120,657,204
AA 41 1.00 0.68 - 1.47 0.218
AG 47 0.76 0.53 - 1.10
GG 19 0.59 0.35 - 1.00
SRGAP2 chr1: 120,808,675 - 
120,832,674
AA 41 1.00 0.82 - 1.21 0.652
chr1: 204,582,823 - 
204,648,014
AG 48 1.03 0.86 - 1.24
GG 19 0.89 0.68 - 1.17
rs11249433 chr1: 120,982,136
+ Based on the UCSC genome browser on Human Mar. 2006 assembly (hg18).
*Generalized linear model adjusted for age, ER and PR status.
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variants of NOTCH2
We tested for potential alternative splicing events within
the NOTCH2 gene by performing a 5' rapid amplification
of cDNA ends (RACE). One of the transcripts with alter-
native 5'end was identical to NOTCH2NL (data not
shown). Another alternative splicing form was tran-
scribed from an alternative exon 1a and was terminated
by an alternative stop codon after exon 16 of the
NOTCH2 gene (GenBank GQ231534). This splicing form
encodes a truncated (TR) protein of 863 amino acids
identical to a fragment of the full-length (FL) NOTCH2
protein (amino acids 40 - 827). The TR-NOTCH2 protein
is predicted to have a dominant negative function relative
to FL-NOTCH2, as it has an extracellular but no intracel-
lular domain (Figure 3A). FL-NOTCH2 protein has 19
epidermal growth factor (EGF)-like repeats, while the
TR-NOTCH2 has only 8 repeats, thus the functional
properties of extracellular domains of these two protein
forms and their interactions with ligands might be differ-
ent.
We cloned both splicing forms of NOTCH2 and exam-
ined their protein expression in human cell lines HeLa
and 293T. NOTCH proteins undergo several stages of
proteolytic cleavages: non-activating cleavage at S1 site
with furin-like convertase occurs during protein process-
ing and generates two protein subunits - extracellular and
transmembrane/intracellular; S2 activating cleavage
occurs in response to ligand binding; S3 activating cleav-
age by γ-secretase generates the notch intracellular
domain (NICD) that migrates to the nucleus and acti-
vates downstream targets [22]. The use of γ-secretase
inhibitors that prevent NOTCH cleavage at S3 site has
been targeted as a promising tool for anti-cancer therapy
[38]. The expected sizes for FL-NOTCH2-Halo and TR-
NOTCH2-Halo expression constructs with C-terminal
Halo-tags are ~298 kDa and ~125 kDa, respectively. The
results of the Western blot (Figure 3B) suggested that the
observed size of ~200 kDa (with Halo-Tag of 33 kDa) for
FL-NOTCH2-Halo is likely to correspond to C-terminal
intracellular part of protein after non-activating S1 cleav-
age. The shorter bands might correspond to forms after
activation cleavage events at S2 and S3 sites. For TR-
NOTCH2-Halo that lacks the cleavage site, low protein
expression was detected by a band of a size correspond-
ing to the unprocessed protein (~125 kDa). Confocal
imaging of both expression constructs showed a differen-
tial pattern of cellular localization for these forms. The
expression pattern for FL-NOTCH2-Halo suggested that
the C-terminal intracellular protein part is localized in
the cytoplasm and in the peri-nuclear space (Figure 3C).
In contrast, the TR-NOTCH2 form, which lacks the
cleavage sites, is found in a granule-type pattern, possibly
anchored to cell membrane (Figure 3D).
mRNA expression of TR-NOTCH2 was lower than that
of FL-NOTCH2 by 10.7 fold in blood samples, by 25.4
fold in tumor breast tissue and by 33.1 fold in normal
breast tissue (Additional File 1, Figure S1). There was also
a great variation in relative expression of FL-NOTCH2
and TR-NOTCH2 in a panel of human tissues and NCI-
60 cancer cell lines, but the significance of this differential
expression is unknown (Additional File 1, Table S7). The
pattern of NOTCH2 mRNA expression in different tumor
types and genotype groups was similar for both forms
(Additional File 1, Table S1, Table S2, and Table S8), but
due to a much lower level of expression of the TR-
Figure 2 NOTCH2 expression in breast tumors. A. Stratified by ER and TP53 mutational status; B. Stratified by genotypes of rs11249433 in TP53wt/
ER+ tumors. Expression is shown as fold difference with 95% confidence intervals compared to reference groups; p-values are for generalized linear 
model adjusted for plate effect, age at diagnosis, race, ER/PR and TP53 mutational status when applicable.
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the results were mostly not statistically significant (Addi-
tional File 1, Table S8). Therefore, the association
between rs11249433 and expression of NOTCH2 in
human breast tumors is likely to be general and unspe-
cific for particular splicing forms. However, as a result of
a much higher expression level of FL-NOTCH2 compared
to TR-NOTCH2 in breast tissue, the effect of FL-
NOTCH2 might be predominant.
Conclusions
Large-scale GWAS for BC identified multiple genomic
regions that harbor genetic risk factors for the disease. In
this study, we aimed to identify a molecular phenotype
related to the recently reported genetic association within
the 1p11.2 region [4]. We found that the BC-associated
rs11249433 located within this region, is associated with
mRNA expression of NOTCH2 gene. Most unexpectedly,
the association between rs11249433 and NOTCH2
expression was dependent on the mutational status of the
tumor suppressor gene TP53 and ER status of the tumors.
Among other scenarios this suggests that either the estro-
gen receptor or the TP53 may have a function in the regu-
lation of NOTCH2 expression, as the restoration of p53
expression has been shown to affect NOTCH1 expression
[39,40]. An active NOTCH pathway is important for the
induction of breast stem cells to differentiate into luminal
cells of breast ducts [41]. Thus, increased or persistent
activation of NOTCH2 expression may favor develop-
ment of ER+ breast carcinomas in TP53wt tumors.
Indeed, the original GWAS association with rs11249433
was stronger in ER+ compared to ER- cancer [4]. Future
research will have to examine how rs11249433 influences
NOTCH2 expression and what function TP53 and the
estrogen receptor may have in regulation of NOTCH2
expression. We also identified the first possible domi-
nant-negative truncated form of NOTCH2. The exact
role of this form in different tissues and biological condi-
tions warrants further studies.
Materials and methods
Human breast tissue and blood samples
Fresh-frozen tumor specimens and blood samples were
obtained from breast cancer patients. The US breast tis-
sue samples (100 tumor samples and 90 adjacent normal
breast tissue) were previously described [42]. Briefly,
patients were recruited at the University of Maryland
Medical Center (UMD), the Baltimore Veterans Affairs
Medical Center, Union Memorial Hospital, Mercy Medi-
cal Center, and the Sinai Hospital in Baltimore between
1993 and 2003. All patients signed a consent form and
completed an interviewer-administered questionnaire.
Clinical and pathological information was obtained from
medical records and pathology reports. Disease staging
Table 2: Summary of PANTHER pathway enrichment analysis for transcripts correlated with NOTCH2 in the NCI-60 set of 
cell lines
PANTHER categorya No. of genes in 
reference list
Observed no. of 
genes in category
Expected no. of 
genes in category
Over(+)/under(-) 
representation
p-valueb
For genes with positive correlation with NOTCH2 expression
BP00285 Cell structure and motility 990 65 27.7 + 6.96 × 10-9
P00034 Integrin signalling pathway 217 26 6.1 + 1.87 × 10-7
MF00091 Cytoskeletal protein 698 47 19.5 + 1.22 × 10-6
BP00125 Intracellular protein traffic 892 51 25.0 + 4.59 × 10-5
MF00261 Actin binding cytoskeletal 
protein
342 29 9.6 + 3.46 × 10-5
For genes with negative correlation with NOTCH2 expression
MF00042 Nucleic acid binding 2214 187 100.1 + 1.88 × 10-17
BP00031 Nucleoside, nucleotide and 
nucleic acid metabolism
2837 203 128.3 + 1.20 × 10-10
BP00047 Pre-mRNA processing 264 35 11.9 + 4.74 × 10-6
BP00048 mRNA splicing 196 29 8.9 + 1.04 × 10-5
aPANTHER accession number for pathway (P), biological process (BP), or molecular function (MF) http://www.pantherdb.org/.
bp-values of binomial test with Bonferroni correction for multiple testing.
Fu et al. Molecular Cancer 2010, 9:113
http://www.molecular-cancer.com/content/9/1/113
Page 7 of 11was performed according to the tumor-node-metastasis
(TNM) system of the American Joint Committee on Can-
cer/the Union Internationale Contre le Cancer (AJCC/
UICC). The Nottingham system was used to determine
the tumor grade. The collection of tumor specimens, sur-
vey data, and clinical and pathological information was
reviewed and approved by the University of Maryland
Institutional Review Board for the participating institu-
tions (UMD protocol #0298229). IRB approval of this
protocol was then obtained at all institutions (Veterans
Affairs Medical Center, Union Memorial Hospital, Mercy
Medical Center, and Sinai Hospital). The project was also
reviewed and approved by the NIH Office of Human Sub-
jects Research (OHSR #2248).
Breast tumor samples from Norway (n = 116) were col-
lected in 1995-1998 from 5 hospitals located in the Oslo
region [43]. Histological tumor type, tumor size, and
nodal involvement were analyzed, and the disease was
staged according to the TNM system. Tumor grading was
performed according to Elston and Ellis [44] and tumor
slides were screened for vascular invasion. Blood samples
(n = 316) were collected from breast cancer survivors
treated with radiotherapy at the Norwegian Radium Hos-
pital between 1998 and 2002 and invited in 2004 to par-
ticipate in a study assessing late clinical and biochemical
effects [45,46]. The project was reviewed and approved
by the NIH Office of Human Subjects Research (OHSR
#4700). Monocytes from fresh blood obtained from
anonymous blood donors at the NIH Blood Bank, were
described previously [47].
Overall, all blood samples were collected from patients
of European ancestry, while for breast tissue 75% samples
were from patients of European ancestry and 25% of Afri-
can ancestry. Race of patients was included as a covariate
in the generalized linear model when relevant.
ER, PR status evaluation
For the US samples, the ER status was determined immu-
nohistochemically using formalin-fixed, paraffin-embed-
ded tissue slides and the ready-to-use monoclonal
antibody (clone 6F11, Ventana Medical Systems, Tucson,
AZ). The ER status was determined according to the ref-
erence range set by the ChromaVision ACIS assisted
quantitative image analysis software (Clarient Diagnostic
Figure 3 Splicing variation of NOTCH2. A. Schematic representation of recombinant constructs for full-length (FL) and truncated (TR) NOTCH2 pro-
tein isoforms fused with C-terminal Halo-tag protein (marked as Halo). Intracellular part of FL-NOTCH2 consists of two LNRs (Lin-12/Notch repeat do-
mains, marked as N), two NOTCH protein domains (marked as NOD), two ankyrin repeats (marked as ANK) and a topoisomerase II-associated protein 
domain (marked as PAT1). B. Western blot showing expression of recombinant FL-NOTCH2-Halo and TR-NOTCH2-Halo constructs in HeLa and 293T 
cell lines. The lanes show two different size markers, negative control (no DNA), mock control (vector only) and results of transfections with FL-
NOTCH2-Halo and TR-NOTCH2-Halo in HeLa and 293T cells. C. Confocal imaging of protein expression for the recombinant construct FL-NOTCH2-
Halo (red) in HeLa cells. Untransfected cells in the same field serve as negative controls. Antibodies against α-tubulin were used to stain the cytoskel-
eton (green) while DAPI was used to stain the cell nuclei (blue). D. Confocal imaging of protein expression for the recombinant construct TR-NOTCH2-
Halo (red) in HeLa cells. Untransfected cells in the same field serve as negative controls. Antibodies against α-tubulin were used to stain the cytoskel-
eton (green) while DAPI was used to stain the cell nuclei (blue).
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The PR status was abstracted from medical records, as
available. For the Norwegian samples, immunostaining
was performed using mouse mAb against estrogen recep-
tor (ER) and progesterone receptor (PgR; clones 6F11 and
1A6, respectively; Novocastra, Newcastle on Tyne,
United Kingdom). Automated immunostaining systems
BioGenex were used for both markers. Immunopositivity
was recorded for tumors with > 10% (ER, PgR) of stain-
ing.
TP53 mutation analysis
Tumors were screened for TP53 mutations as previously
described [43,48].
RNA preparation
Total RNA from fresh-frozen breast tissue samples was
isolated using TRIZOL reagent according to the manu-
facturer's instructions (Invitrogen, Carlsbad, CA). Total
RNA from blood cells was isolated from PAX tubes at
AROS Applied Biotechnology (Aarhus, Denmark) with
an automated procedure utilizing the column-based
technologies from Qiagen Inc. (Hilden, Germany). The
concentration was measured using a NanoDrop spectro-
photometer (NanoDrop Technologies, Wilmington, DE).
RNA integrity for each sample was confirmed with the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA).
cDNA preparation
For each sample, 200-300 ng of total RNA was converted
to cDNA with Superscript III kit (Invitrogen) for the US
samples or with High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA) for the
Norwegian samples.
Microarray expression of 5 genes with Agilent 44K whole-
genome microarrays
mRNA expression values for ADAM30, NOTCH2,
NOTCH2NL, FAM72B, and SRGAP2 were extracted from
a whole-genome expression set for breast tumor samples
from Norway (unpublished data Edvardsen, et al.) gener-
ated with Agilent whole human genome 44K 60-mer
oligo arrays, Agilent Technologies). The arrays were
scanned using the Agilent scanner G2565A and signals
were extracted using Feature Extraction v9.5. Data were
log2 transformed and, after removal of non-uniform
spots and exclusion of population outliers, replicated
probes were averaged. The data were quintile normalized
using the R package "normalize Between Arrays" from the
LIMMA library [49] and missing values imputed using
LLS imputation [50]. Information on genotypes, age, ER
and PR status was available for 108 breast cancer samples
with expression values.
Genotyping
Pre-developed TaqMan allelic discrimination genotyping
assays for SNPs rs11249433 (C___31617470_30) and
rs10923931 (C___1188816_10) were purchased from
Applied Biosystems. Genotyping was performed in 384-
well optical plates on the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems) with 10 ng of
genomic non-tumor DNA, 0.125 μL of 40 × TaqMan SNP
genotyping assay, 2.5 μL of 2 × TaqMan genotyping mas-
ter mix (Applied Biosystems) in 5 μL reaction volume.
Quantitative Reverse-Transcriptase PCR (qRT-PCR)
Expression of NOTCH2 was measured with two custom-
designed assays, FL-NOTCH2, targeting a junction
between the most terminal exons 33 and 34 and TR-
NOTCH2 for the truncated form (information about all
assays is presented in Additional File 1, Table S6). Three
endogenous controls, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), beta-2-microglobulin (B2 M) and
cyclophilin (PPIA), were selected as appropriate controls
based on prior expression studies in breast cancer [51].
All assays were validated on a cDNA panel prepared from
a normal breast tissue sample at 8 different RNA concen-
trations: 1000 ng/μL, 100 ng/μL, 10 ng/μL, 1 ng/μL, 0.1
ng/μL, 0.01 ng/μL, 0.001 ng/μL, and 0 ng/μL. Standard
curves constructed for each assay were used for calcula-
tion of amplification efficiency (E, %). To determine opti-
mal amount of cDNA to be used for each assay, several
samples representing each tissue type were tested at three
5-fold dilutions of cDNA. We used 2.4 ng of total RNA/
reaction for TR-NOTCH2 assay and 0.6 ng of total RNA/
reaction for all other assays. All plates included two nega-
tive controls (genomic DNA and water), and three posi-
tive controls prepared from total RNA of MCF7 breast
cancer cell line and used at three 5-fold dilutions of
cDNA. The positive controls were also used as interplate
controls to normalize results between plates. All assays
were run in quadruplicates on 384-well plates on ABI
PRISM 7900HT Sequence Detection System (Applied
Biosystems). For endogenous controls, the reactions were
performed with cDNA prepared from 0.6 ng of total
RNA, 0.25 μL of 20 × TaqMan expression assay and 2.5
μL of 2 × TaqMan Gene Expression master mix (Applied
Biosystems) in 5 μL reaction volume. For NOTCH2
assays, the reactions were performed with cDNA pre-
pared from 0.6 or 2.4 ng of total RNA, custom-designed
primers, 2.5 μL of 2 × Power SYBR master mix (Applied
Biosystems) in 5 μL reaction volume.
CNV analysis
Two assays were used to quantify CNV around NOTCH2
region (Additional File 1, Table S9 for assay information).
A CNV assay BC1 was designed to map upstream
Fu et al. Molecular Cancer 2010, 9:113
http://www.molecular-cancer.com/content/9/1/113
Page 9 of 11NOTCH2 and a CNV assay BC2 located within intron 1
of NOTCH2, was designed next to an assay that was pre-
viously used to validate genomic amplification of this
region (Supplementary Table 4 of [31], Chr1tp-38C8,
chr1: 120,245,520-120,395,759). Each of assays was quan-
tified with qPCR using 5 ng of genomic DNA from corre-
sponding samples (blood or tumor) and 2 × Power SYBR
master mix (Applied Biosystems). All plates included two
negative controls (water), and three positive controls (20
ng, 4 ng and 0.8 ng of a normal DNA sample). The posi-
tive controls were also used as interplate controls to nor-
malize results between plates. All assays were run in
quadruplicates on 384-well plates on ABI PRISM
7900HT Sequence Detection System (Applied Biosys-
tems). The CNV assays were normalized by a control
RNAseP assay (Applied Biosystems) run in quadrupli-
cates in separate reactions.
Pathway analysis
Expression data of NCI-60 cell lines on Affymetrix HG-
U133 arrays that included 39,135 probes covering 18,457
unique annotated transcripts was downloaded from
CellMiner Build1.0 [34]. The probe (212377_s_at) resid-
ing on the junction of exons 33 and 34 of NOTCH2 (simi-
larly to FL-NOTCH2 expression assay) was selected to
calculate the pairwise Pearson's correlation coefficient
between this probe and all other probes on HG-U133
chip across the entire NCI-60 cancer cell panel. The false
discovery rate (FDR) [52] was set at 5%, defining the
threshold for correlation coefficient as r = +/- 0.39. The
lists of genes that showed significantly positive or nega-
tive correlations with NOTCH2 expression were used to
determine enrichment for any pathway, biological pro-
cess, or molecular function using the Compare Gene Lists
Tool from the PANTHER Classification System [53] rela-
tive to the reference gene list that included all 39,135
probes represented on Affymetrix HG-U133 arrays.
Genes that showed positive and negative association with
NOTCH2 were examined separately and the Bonferroni
correction was applied for multiple testing.
Statistical analyses
Expression analysis was performed as follows: for each
assay, the mean values of quadruplicates were recalcu-
lated based on standard curve slopes to correspond to E =
100% of amplification efficiency as E = -1+10(-1/slope) http:/
/www.stratagene.com/techtoolbox/calc/
qpcr_slope_eff.aspx. Distribution of expression values for
each of the assays was tested for normality and no signifi-
cant deviations were observed. The values for all assays
were normalized to interplate controls on each plate. The
expression values for NOTCH2 assays were normalized
by the geometric mean of all endogenous controls
(GAPDH, B2 M and PPIA) according to relative quantifi-
cation method (dCt) [54]. A generalized linear model
adjusted for applicable covariates (plate effect, age at
diagnosis, race, ER/PR and TP53 mutation status) was
used to test the association between mRNA expression
and SNPs. For correlation analysis, Pearson's correlation
coefficients and FDR-adjusted p-values were calculated.
All the statistical analyses were performed using SAS/
STAT system version 9.2 (SAS Institute Inc., Cary, NC).
NOTCH2 cDNA cloning, transfection, Western blot and 
confocal imaging
5'RACE was performed starting with a mix of total RNA
from normal and cancer breast tissue. The 5'RACE cDNA
was prepared with SMART RACE cDNA Amplification
Kit (Clontech, Mountain View, CA). Using the 5'RACE
cDNA as a template, PCR fragments were amplified with
a primer for exon 4 of NOTCH2 and a universal RACE
linker attached to 5'end of transcripts. After sequencing
and analysis of the PCR fragments, a novel alternative
transcription start and exon 1a were identified. Using
primers for two transcription starts and two translation
stops predicted in the UCSC browser, all four combina-
tions of PCR reactions were attempted on a breast tumor
and a normal sample (primers are presented in Addi-
tional File 1, Table S9). The successful PCR products were
cloned into a pFC8A Halo-tag CMV Flexi vector (Pro-
mega, Madison, WI) and multiple clones were sequenced.
Only two splicing forms were identified - a known form
(NM_024408), representing the full-length FL-NOTCH2
and a novel splicing form, TR-NOTCH2 (GenBank
GQ231534). Equal amounts of the constructs were trans-
fected into human HeLa and 293T cell using Lipo-
fectamine 2000 reagent according to instructions
(Invitrogen). Non-transfected cells (Lipofectamine only)
and cells transfected with empty GFP-tagged pIRES vec-
tor (Clontech) served as negative controls. Protein lysates
from transfected cells were prepared 48 hours post-trans-
fection and analyzed by Western blot. Similar amounts of
protein for each sample were resolved on 4-12% tris-gly-
cine polyacrylamide gel (Invitrogen) together with pre-
stained Rainbow marker (BenchMark Prestained Protein
Ladder, Invitrogen) and Santa-Cruz protein marker (sc-
2035, Cruz Marker Molecular Weight Standards, Santa
Cruz, CA), transferred to nitrocellulose membrane
(Invitrogen), blocked with 5% milk and probed with rab-
bit anti-Halo (Promega) and mouse α-tubulin primary
antibodies (ab-7291, Abcam, Cambridge, MA), both at
1:1000 dilution, followed by incubation with secondary
HRP-labeled antibodies (sc-2305 donkey anti-rabbit and
sc-2302 goat anti-mouse, Santa Cruz, at 1:10,000 dilu-
tion) and ECL-detection (GE Healthcare, Pittsburgh, PA).
For immunofluorescence analysis, the cells were grown
on chamber slides and transfected with the expression
constructs with Lipofectamine 2000 reagent according to
Fu et al. Molecular Cancer 2010, 9:113
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cells were permeabilized with 4% of paraformaldehyde,
blocked with 4% BSA in TBS for 1 hr, and incubated with
primary rabbit Anti-Halotag antibody (Promega), and
mouse α-tubulin (ab-7291, Abcam), both at 1:1000 dilu-
tion. Cells were incubated with secondary antibody (don-
key anti-rabbit Alexa Fluor 594 and donkey anti-mouse
Alexa Fluor 488, Invitrogen, both at 1:10,000 dilution) for
1 hr. Slides were covered with mounting media (Prolong
Gold antifade reagent with DAPI, Invitrogen) and images
were collected with a confocal laser scanning microscope
(LSM 510 META, Carl Zeiss Jena GmbH, Jena, Germany)
at ×63 magnification with oil.
Bioinformatics analysis of protein domains
Sequences for NOTCH2 splicing forms were analyzed for
presence of open reading frames http://www.ncbi.nlm.
nih.gov/projects/gorf/ and putative conserved domains
http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi.
Molecular weight of protein isoforms was calculated with
Protein Calculator v3.3 http://www.scripps.edu/~cdput-
nam/protcalc.html.
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